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Coronavirus 2019 (COVID-19) has led to a rapid increase in hospital admissions, placing 
stress on healthcare systems that have a finite number of hospital beds, healthcare providers 
(HCPs), and medical supplies.  Preliminary data suggest that hydroxychloroquine (HCQ) and 
azithromycin (AZM) may improve the clinical course in patients with COVID-19. (1,2)  
However, HCQ±AZM may increase the risk for arrhythmias and sudden cardiac death due to QT 
prolongation. (3,4)  Given the widespread use of HCQ±AZM, it is challenging to monitor all of 
these inpatients on telemetry.  Performing serial electrocardiograms (ECGs) for QTc monitoring 
increases HCP exposures and personal protective equipment (PPE) use.   
We placed Mobile Cardiac Outpatient Telemetry (MCOT) (BioTelemetry, Malvern, PA, 
USA) on patients receiving HCQ±AZM for COVID-19 on non-telemetry floors.  Following a 
baseline ECG, subsequent ECGs were cancelled.  Telemetry technicians applied the MCOTs and 
linked them to the device phone. Patients had bidaily QTc measurements while receiving 
HCQ±AZM.  An electrophysiologist received “urgent alerts” and bidaily reports from 
BioTelemetry.  A QTc>500ms and any arrhythmias generated “urgent alerts.”  If a patient was 
discharged to complete HCQ±AZM as an outpatient or remained hospitalized after completing 
HCQ±AZM, the MCOT was removed, sterilized, and reused. 
In one week, 117 consecutive COVID-19-positive patients on HCQ±AZM without 
telemetry monitors received an MCOT.  The average age was 60.2±14.9 years (range 27-93 
years); 40.5% were female, 52.1% had hypertension, 28.2% had diabetes, 0.9% had heart failure, 
and 5.1% had coronary artery disease. All patients were treated with HCQ 400mg bidaily for one 
day followed by 200mg bidaily for four days.  Fifty-one (43.6%) patients also received ≥1 doses 
of intravenous azithromycin 500mg.  Forty (34.2%) patients also received ≥1 other QT 
prolonging medications.  Over the course of 295 total patient days, there were 28 urgent alerts 
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for 18 (15.4%) patients.  Atrial fibrillation (AF) with a rapid ventricular response was the most 
common (15, 53.6%).  There were five (17.9%) alerts for QTc>500ms (Table 1).  An 
electrophysiologist was contacted for urgent events within 3-5 minutes.  Of the 28 urgent alerts, 
12 did not warrant intervention (e.g. first-degree atrioventricular block).   
From a baseline mean QTc of 437.1±22.2ms, the average increase in QTc for the entire 
population was 33.9±26.8ms (Table 1).  The maximum QTc was similar in patients treated with 
HCQ versus HCQ+AZM (448.5±33.7ms vs. 451.9±29.2ms, p=0.58).  The change in QTc from 
baseline was also similar (32.1±25.1ms vs. 35.7±28.9ms, p=0.66).  HCQ was discontinued in 
one patient after three days due to QTc prolongation from 460ms to 565ms. 
This study demonstrates that when hospital admission rates exceed the capacity of 
telemetry beds, the MCOT may be used to monitor for arrhythmias and assess the QTc.  In 2017, 
the MCOT, which consists of a sensor and monitor network that communicate via Bluetooth, 
was FDA-approved for QTc measurement, analysis, and reporting.  Once gathered, the data is 
forwarded to the monitor for analysis.  After each use, MCOT may be rapidly “redeployed” to 
another patient.   
In our experience, twenty-eight “urgent alerts” were communicated in near real-time to 
an electrophysiologist, of which 16 alerts resulted in management changes.  In addition to the 
“urgent alerts,” the MCOT afforded electrophysiologists the ability to monitor for QTc changes.  
While HCQ±AZM may put patients at higher risk for drug-induced arrhythmias, none of our 
patients had arrhythmias that led to medication discontinuation.  The MCOT also allowed for 
better utilization of HCPs and resources.  By eliminating the need for serial ECGs, we reduced 
both HCP exposures and PPE use.   
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The limitations of MCOT include that the device was never approved to measure QTc for 
patients with AF or atrial flutter, QRS >160ms, and T-wave <5% of the peak QRS amplitude.  
The single-center, non-randomized study design, and a healthy population from a cardiac 
standpoint, are other limitations.  The MCOT must be used with caution in patients with 
significant cardiac disease.   
In conclusion, innovative management of COVID-19 patients treated with HCQ±AZM is 
needed given the limited healthcare resources.  The MCOT may be utilized for arrhythmia and 
QTc monitoring while reducing both HCP exposures and PPE use.  
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Table 1: MCOT Urgent Alerts and QTc Measurement of the Study Cohort 
 
Urgent Alerts (N=28) 
Atrial Fibrillation with a Rapid Ventricular Response 15 (53.6%) 
QTc >500ms 5 (17.9%) 
First Degree Atrioventricular Block 4 (14.3%) 
Nonsustained Ventricular Tachycardia 2 (7.1%) 
Ventricular Bigeminy 1 (3.6%) 
Supraventricular Tachycardia 1 (3.6%) 
QTc Measurements 
QTc Parameters Overall 
(N=117) 
HCQ 
(N=66) 
HCQ+AZM 
(N=51) 
P-Value 
Baseline QTc 437.1 ± 22.2 438.1 ± 23.8 435.8 ± 19.9 0.591 
Maximal QTc 449.9 ± 31.7 448.5 ± 33.7 451.9 ± 29.2 0.575 
Maximal QTc – Baseline 
QTc 
33.9 ± 26.9 32.1 ± 25.1 35.7 ± 28.9 0.662 
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Final QTc 441.2 ± 28.7 440.0 ± 32.1 443.3 ± 23.6 0.54 
Final QTc – Baseline QTc 7.3 ± 30.7 3.9 ± 31.9 12.8 ± 29.3 0.247 
Values listed are numbers (percentages) or means±standard deviations. AZM=Azithromycin; 
HCQ=Hydroxychloroquine; QTc=Corrected QT. 
